Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Specific antibody deficiency in children with recurrent respiratory infections: a controlled study with follow-up.

Ruuskanen O, Nurkka A, Helminen M, Viljanen MK, Käyhty H, Kainulainen L.

Clin Exp Immunol. 2013 May;172(2):238-44. doi: 10.1111/cei.12053.

2.

Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine.

Simell B, Nurkka A, Ekström N, Givon-Lavi N, Käyhty H, Dagan R.

Clin Vaccine Immunol. 2012 Oct;19(10):1618-23. Epub 2012 Aug 8.

3.

Association of serotype-specific antibody concentrations and functional antibody titers with subsequent pneumococcal carriage in toddlers immunized with a 9-valent pneumococcal conjugate vaccine.

Simell B, Nurkka A, Lahdenkari M, Givon-Lavi N, Käyhty H, Dagan R, Jokinen J.

Clin Vaccine Immunol. 2012 Jan;19(1):96-9. doi: 10.1128/CVI.05369-11. Epub 2011 Nov 9.

4.

Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines.

Poolman J, Frasch C, Nurkka A, Käyhty H, Biemans R, Schuerman L.

Clin Vaccine Immunol. 2011 Feb;18(2):327-36. doi: 10.1128/CVI.00402-10. Epub 2010 Dec 1.

5.

Results from an inter-laboratory comparison of pneumococcal serotype-specific IgG measurement and critical parameters that affect assay performance.

Balloch A, Licciardi PV, Leach A, Nurkka A, Tang ML.

Vaccine. 2010 Feb 3;28(5):1333-40. doi: 10.1016/j.vaccine.2009.11.011. Epub 2009 Nov 21.

PMID:
19932671
6.

Pneumococcal conjugate vaccine is immunogenic in lung fluid of HIV-infected and immunocompetent adults.

Gordon SB, Kayhty H, Molyneux ME, Haikala R, Nurkka A, Musaya J, Zijlstra EE, Lindell D, French N.

J Allergy Clin Immunol. 2007 Jul;120(1):208-10. Epub 2007 Jun 4. No abstract available.

7.

Salivary antibodies induced by the seven-valent PncOMPC conjugate vaccine in the Finnish Otitis Media Vaccine Trial.

Nurkka A, Lahdenkari M, Palmu AA, Käyhty H; FinOM Study Group.

BMC Infect Dis. 2005 May 27;5:41.

8.

[Lack of spleen or spleen malfunction--serious risk factor for sepsis].

Kanerva M, Varpula T, Carlson P, Kaijalainen T, Nurkka A, Käyhty H, Seppänen M.

Duodecim. 2004;120(20):2459-62. Finnish. No abstract available.

PMID:
15641515
9.

Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants.

Nurkka A, Joensuu J, Henckaerts I, Peeters P, Poolman J, Kilpi T, Käyhty H.

Pediatr Infect Dis J. 2004 Nov;23(11):1008-14.

PMID:
15545855
10.

Salivary antibodies induced by the seven-valent PncCRM conjugate vaccine in the Finnish Otitis Media Vaccine Trial.

Nurkka A, Lahdenkari M, Palmu A, Käyhty H; FinOM Study Group.

Vaccine. 2004 Dec 2;23(3):298-304.

PMID:
15530671
11.

Effects of sample collection and storage methods on antipneumococcal immunoglobulin A in saliva.

Nurkka A, Obiero J, Käyhty H, Scott JA.

Clin Diagn Lab Immunol. 2003 May;10(3):357-61.

12.
13.

Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine.

Nurkka A, Ahman H, Korkeila M, Jäntti V, Käyhty H, Eskola J.

Pediatr Infect Dis J. 2001 Jan;20(1):25-33.

PMID:
11176563
14.

Salivary antibody response to vaccination with meningococcal A/C polysaccharide vaccine in previously vaccinated and unvaccinated Gambian children.

Nurkka A, MacLennan J, Jäntti V, Obaro S, Greenwood B, Käyhty H.

Vaccine. 2000 Oct 15;19(4-5):547-56.

PMID:
11027820

Supplemental Content

Loading ...
Support Center